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Peritoneal sclerosis is a major and serious complication in
patients on long-term continuous ambulatory peritoneal
dialysis (PD). The involvement of angiogenesis and
proangiogenic factors such as vascular endothelial growth
factor (VEGF)-A in progressing peritoneal sclerosis has been
reported. We previously reported the therapeutic efficacy of
endostatin peptide, a potent inhibitor of angiogenesis derived
from type XVIII collagen, in a mouse diabetic nephropathy
model. Here, we examined the therapeutic effect of endostatin
peptide in preventing progression in a mouse peritoneal
sclerosis model. Male ICR mice received intraperitoneal
injections of chlorhexidine gluconate (CG) every other day to
induce peritoneal sclerosis. Endostatin peptide (1 or 4 mg/kg/
day) was administered via subcutaneously implanted osmotic
minipumps. Peritoneal sclerosis (day 24) was significantly
suppressed by endostatin peptide in a dose-dependent
manner. Peritoneal accumulation of type III collagen was
significantly suppressed by endostatin peptide. Increase in the
number of CD31(þ ) blood vessels, F4/80(þ ) monocyte/
macrophage accumulation, and 5-bromodeoxyuridine(þ )
proliferating cells was significantly inhibited by endostatin
peptide. Increase in peritoneal expression of VEGF-A, profibrotic
transforming growth factor-b1, and a-smooth muscle actin was
suppressed by endostatin peptide. Immunoreactivity for
endogenous endostatin (whole molecule) and endostatin
receptor a5b1-integrin was increased and colocalized to
CD31(þ ) blood vessels in the thickened peritonea of CG-
injected mice. These results demonstrate the potential use of
antiangiogenic endostatin peptide as a novel therapeutic agent
in preventing peritoneal sclerosis, a severe complication in
patients undergoing long-term PD.
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Peritoneal dialysis (PD) is a beneficial treatment for patients
with end-stage renal diseases. However, long-term PD
treatment is associated with histopathological alterations in
the peritoneum owing to continuous exposure to bioincom-
patible dialysate components as well as repeated episodes of
bacterial peritonitis.1,2 Characteristic features of peritoneal
alterations include peritoneal fibrosis with accumulation of
the extracellular matrix in the submesothelial area and loss of
mesothelial cells.3 Some patients develop encapsulating
peritoneal sclerosis (EPS) associated with high mortality,
and this serious complication of PD is characterized by
progressive fibrosis in the peritoneum.4 Increased peritoneal
vascular density accompanied by vascular alterations has
been observed in patients on long-term PD, suggesting the
involvement of vascular alterations in peritoneal dysfunc-
tion.5–7
The peritoneal membrane is lined with a monolayer of
mesothelial cells possessing some characteristics of epithelial
cells.8 Epithelial mesenchymal transition (EMT), a process
involved in various physiological as well as pathological
conditions such as tumor metastasis,9 has been identified in
peritoneal mesothelial cells in vitro10 and in patients on long-
term PD.11 The pivotal role of the profibrotic growth factor
transforming growth factor (TGF)-b1 in inducing EMT of
mesothelial cells has been demonstrated using cultured
peritoneal mesothelial cells10 and by the experimental TGF-
b1 gene transfer approach in the rat peritoneum.12 EMT is
characterized by the loss of intercellular junctions, loss of
polarity, acquisition of a myofibroblast-like phenotype with
the expression of a-smooth muscle actin (SMA) and
migratory behavior.9
Angiogenesis, the development of new blood vessels from
pre-existing ones, is involved in physiological events such as
wound repair, but uncontrolled neovascularization is asso-
ciated with a number of pathological disorders including
tumor growth, rheumatoid arthritis, and diabetic retino-
pathy.13 Williams et al.3 observed a correlation between
peritoneal vascular density and peritoneal fibrosis in patients
on long-term PD, suggesting that vasculopathy may predis-
pose these patients to the development of peritoneal fibrosis.
Vascular endothelial growth factor (VEGF-A), a potent
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stimulator of angiogenesis, promotes endothelial cell pro-
liferation, migration, and tube formation.14 VEGF-A is also
known to induce vascular permeability associated with
inflammation and pathological conditions.15 The protein
levels of VEGF-A in the peritoneum were reported to be
upregulated in patients on long-term PD16 in accordance
with a rat EPS model showing a gradual increase in VEGF
messenger RNA in the peritoneum.17 The therapeutic effect
of neutralizing anti-VEGF antibodies in preventing perito-
neal sclerosis in the latter experimental rat model renders
further support for the involvement of angiogenesis and
VEGF in peritoneal sclerosis.17 A recent report describes
increased VEGF synthesis in effluent mesothelial cells
undergoing EMT that were obtained from PD patients,18
suggesting an association between EMT and VEGF in the
progression of peritoneal sclerosis. An angiogenesis inhibitor,
TNP-470, suppressed the progression of peritoneal fibrosis in
a mouse experimental model, further suggesting the involve-
ment of angiogenesis in peritoneal sclerosis.19
Endostatin, a 20-kDa C-terminal non-collagenous domain
1 of type XVIII collagen, possesses potent antiangiogenic
activity.20 Endostatin inhibits endothelial cell proliferation,
migration, and tube formation in vitro,21 and inhibits tumor
growth in vivo.20 The inhibitory effects of endostatin on the
expression of VEGF-A in tumor cells and on vascular
permeability has been reported.22 Recent reports have
demonstrated the antiangiogenic activity of synthetic peptide
derived from the N-terminal domain of endostatin.23,24
Several reports have indicated possible cell-surface receptors
for the antiangiogenic activity of endostatin, that is, a5b1-
integrin or glypicans.25,26 We recently reported the ther-
apeutic efficacy of endostatin peptide treatment in amelior-
ating early alterations in a diabetic nephropathy mouse
model.27
In this study, we demonstrate the therapeutic efficacy of
endostatin peptide in ameliorating alterations in a chlorhex-
idine gluconate (CG)-induced mouse peritoneal sclerosis
model. Treatment with endostatin peptide markedly sup-
pressed thickening of the peritoneum, as well as the
accumulation of submesothelial interstitial collagens and
monocytes/macrophages. These effects were supposed to be
mediated through the downregulation of VEGF, TGF-b1, and
by ameliorating the transdifferentiation of peritoneal me-
sothelial cells.
RESULTS
Histology and morphometric analysis
Morphologic changes of the parietal peritoneum were
analyzed by Masson’s trichrome staining. In the normal
mice, a monolayer of mesothelial cells was observed covering
the surface without any thickening of the peritoneum (Figure
1a). The appearance of the peritoneum of mice receiving
intraperitoneal injection of 15% ethanol dissolved in saline
was similar to that of the normal mice (Figure 1e).
Intraperitoneal injection of CG every other day for a period
of 24 days resulted in marked thickening of the submesothe-
lial compact zone and increased cellularity (Figure 1b). The
thickness of the submesothelial zone and increased cellularity
induced by CG were suppressed by the administration of
endostatin peptide (Figure 1c and d). Morphologic evalua-
tion revealed a significant inhibitory effect of endostatin
peptide on CG-induced peritoneal thickening in a dose-
dependent manner (normal control 2.170.1 mm; CG-in-
jected mice treated with the vehicle 318.6718.6 mm; CG-
injected mice treated with endostatin peptide at 1 mg/kg
230.4724.2 mm; and CG-injected mice treated with endo-
statin peptide at 4 mg/kg 158.7714.3 mm, Figure 1f).
Immunohistochemical analysis of CD31 and VEGF
We next examined the expression of endothelial cell marker
CD31 in the peritoneum. The number of CD31(þ ) vessels in
the peritoneum was markedly increased by CG injection
compared with the normal control group (Figure 2a and b).
Treatment with endostatin peptide significantly suppressed
the increase in the number of CD31(þ ) vessels in the
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Figure 1 | Histological appearance of peritoneum. (Representative
light microscopic appearance of peritoneal tissues (Masson’s
trichrome staining,  100 original magnification, day 24) for the (a)
control group, (b) CG-injected group (intraperitoneal) treated with
the vehicle, CG-injected group treated with endostatin peptide at a
dosage of (c) 1 or (d) 4 mg/kg and (e) 15% ethanol/saline-injected
mice. (f) The increased thickness of submesothelial collagenous zone
in the CG-injected mice was dose dependently diminished by
treatment with endostatin peptide. Peritoneal thickness was
determined as described in the ‘Materials and Methods’. *Po0.05 vs
C. #Po0.05 vs V. n¼ 6. C, control; V, CG-injected mice treated with
the vehicle buffer; E1, CG-injected mice treated with endostatin
peptide (1 mg/kg); E4, CG-injected mice treated with endostatin
peptide (4 mg/kg). Each column consists of means7s.e.
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peritoneum induced by CG in a dose-dependent manner
(normal control 0.670.6; CG-injected mice treated with the
vehicle 80.776.9; CG-injected mice treated with endostatin
peptide at 1 mg/kg 45.273.8; and CG-injected mice treated
with endostatin peptide at 4 mg/kg 32.275.4, /10 fields,
Figure 2c and d). We also assessed the number of VEGF-
A(þ ) cells in the peritoneum associated with increased
CD31(þ ) vessels following CG-injection. The number of
peritoneal VEGF-A(þ ) cells was markedly increased by CG-
injection compared with the normal control group
(212.576.1 vs 15.774.1 /10 fields, respectively, Figure 3a).
Immunoreactivity for VEGF-A was observed in mesothelial
cells (Figure 3c), endothelial cells, and fibroblast-like cells in
the peritoneum (Figure 3d), which is consistent with
reported observations.19 Treatment with endostatin peptide
significantly decreased the increase in the number of VEGF-
A(þ ) cells induced by CG in a dose-dependent manner
(CG-injected mice treated with endostatin peptide at 1 mg/kg
142.2716.5; and CG-injected mice treated with endostatin
peptide at 4 mg/kg 113.878.9, /10 fields, Figure 3b and e).
The number of CD31(þ ) vessels and VEGF-A(þ ) cells
per submesothelial area (mm2) was also determined. Similar
to the results obtained as the number per field, the
therapeutic effects of endostatin peptide were observed
(Table 1), suggesting that the reduction of the number of
CD31(þ ) vessels and VEGF-A(þ ) cells was not merely a
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Figure 2 | Immunohistochemical analysis of CD31. (a) Distribution
of CD31-positive blood vessels in the peritoneum was determined by
immunohistochemistry as described in ‘Materials and Methods’ for
the control group, (b, e, and f) CG-injected group (intraperitoneal)
treated with the vehicle, or endostatin peptide at a dosage of (c) 1 or
(d) 4 mg/kg. (f) No immunoreactivity was observed in sections
incubated with normal IgG in place of primary antibody.
Representative light microscopic appearance of the peritoneum is
shown (a–d:  200, e and f:  400 original magnification). (b and e,
arrows) Numerous vessels stained for CD31 were observed in the
thickened submesothelial zone of CG-injected mice. (g) Measurement
of the number of CD31-positive vessels (per 10 fields at  400
original magnification) showed a dose-dependent inhibitory effect of
endostatin peptide treatment on the increase in CD31-positive vessel
density induced by CG. *Po0.05 vs C. #Po0.05 vs V. n¼ 6.
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Figure 3 | Immunohistochemistry of VEGF-A. (a, c, and d) The
distribution of VEGF-A in the peritoneum was examined by indirect
immunohistochemistry for the CG-injected group (intraperitoneal)
treated with the vehicle, or (b) endostatin peptide at a dosage of
4 mg/kg. (c, arrows) VEGF-A-positive cells were mesothelial cells, (d,
arrowheads) endothelial cells and (d, arrows) fibroblast-like spindle-
shaped cells. The representative light microscopic appearance of the
peritoneum is shown (a, b:  200; c, d:  400 original magnification).
(e) Measurement of the number of VEGF-A-positive cells (per 10 fields
at  400 original magnification) showed the significant inhibitory
effect of endostatin peptide. *Po0.01 vs C. #Po0.01 vs V. n¼ 6. Each
column consists of means7s.e.
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reflection of reduced submesothelial tissue volume. These
results demonstrate that treatment with endostatin peptide
resulted in the inhibition of increase in the peritoneal
CD31(þ ) blood vessels induced by CG-injection, possibly
via its potent antiangiogenic efficacy.
Immunohistochemical analysis of type III collagen, a-SMA,
and TGF-b
To examine the effects of endostatin peptide on peritoneal
fibrosis induced by CG, we next examined the accumulation
of type III collagen. Marked accumulation of type III collagen
in the submesothelial zone was observed in the vehicle-
treated CG-injected group compared to the normal control
group (6.3070.35 vs 1.6970.03 105 pixels, respectively,
Figure 4a). Treatment with endostatin peptide inhibited the
accumulation of type III collagen induced by CG in the
peritoneum (CG-injected mice treated with endostatin
peptide at 1 mg/kg 3.2170.42 105 pixels; and CG-injected
mice treated with endostatin peptide at 4 mg/kg
3.1070.38 105 pixels Figure 4b and g). We also examined
the expression of profibrotic growth factor TGF-b and the
number of a-SMA-expressing myofibroblasts in the perito-
neum associated with peritoneal fibrosis. In the normal
control group, TGF-b(þ ) cells were rarely observed and the
expression of a-SMA was only observed in vascular smooth
muscle cells. The vehicle-treated, CG-injected mice exhibited
increased expression of a-SMA in myofibroblasts in addition
to vascular smooth muscle cells in the peritoneum (Figure
4c). Immunoreactivity for a-SMA was observed in the
submesothelial area and in the fibrotic layer. Treatment with
endostatin peptide dose-dependently inhibited the increase
in a-SMA(þ ) myofibroblasts induced by CG in the
peritoneum (normal control 5.071.2; CG-injected mice
treated with the vehicle buffer 238.3715.4; CG-injected mice
treated with endostatin peptide at 1 mg/kg 148.279.9; and
CG-injected mice treated with endostatin peptide at 4 mg/kg
113.575.1 /10 fields, Figure 4c–f and h). The number of
TGF-b-expressing cells in the peritoneum was also increased
in the vehicle-treated CG-injected group compared to the
normal controls. Immunoreactivity for TGF-b was observed
in the submesothelial area and in the fibrotic layer, similar to
the pattern observed for a-SMA (Figure 5a and e). Treatment
with endostatin peptide resulted in the dose-dependent
suppression of the increase in TGF-b(þ ) cells in the
peritoneum (normal control 5.771.5; CG-injected mice
treated with the vehicle 264.378.7; CG-injected mice treated
with endostatin peptide at 1 mg/kg 195.077.5; and CG-
injected mice treated with endostatin peptide at 4 mg/kg
171.079.8/10 fields, Figure 5b, e, and g).
The number of TGF-b(þ ) and a-SMA(þ ) cells per
submesothelial area (mm2) was also determined. Similar to
the results obtained as the number per field, therapeutic
effects of endostatin peptide were observed (Table 1),
suggesting that the reduction in the number of TGF-b(þ )
and a-SMA(þ ) cells was not merely a reflection of reduced
submesothelial tissue volume.
Protein levels of VEGF-A and TGF-b detected by immunoblot
The effect of endostatin peptide on the protein levels of
VEGF and TGF-b in peritoneum was further evaluated by
immunoblot assay to quantitatively confirm the results on
these factors obtained by immunohistochemistry. The levels
of VEGF were significantly increased in the vehicle-treated
CG-injected mice, compared to the undiseased control mice
(Figure 6a and b). Treatment with endostatin peptide
significantly suppressed the increase in VEGF in the CG-
injected mice (Figure 6a and b). The protein level of TGF-b
was also significantly reduced in the CG-injected mice treated
with endostatin peptide compared with the CG-injected mice
treated with the vehicle (Figure 6a and b).
Immunohistochemical analysis of monocyte/macrophage
accumulation
We next examined the expression of mouse monocyte/
macrophage surface marker F4/80 in the peritoneum. In the
vehicle-treated, CG-injected mice, the number of F4/80-
positive cells was significantly increased compared to the
normal control group (83.8710.1 vs 0.670.6, respectively,
Figure 5c and f). Treatment with endostatin peptide
markedly decreased the accumulation of monocytes/macro-
phages in the peritoneum in a dose-dependent manner,
suggesting the anti-inflammatory action of endostatin
peptide in this model (CG-injected mice treated with
endostatin peptide at 1 mg/kg 56.876.7; and CG-injected
Table 1 | Morphometric analysis of immunohistochemical findings
CG-treated vehicle Endostatin peptide (1 mg/kg) Endostatin peptide (4 mg/kg)
CD31(+) vessels (/mm2) 129.3712.0 72.376.2a 51.279.0a
VEGF(+) cells (/mm2) 212.576.1 142.2716.4a 113.878.9a
a-SMA(+) cells (/mm2) 363.8717.0 239.4713.8a 180.578.9a,b
TGF-b(+) cells (/mm2) 434.4728.1 340.2721.7a 302.1725.8a
F4/80(+) cells (/mm2) 83.8710.1 56.876.7a 40.273.8a
BrdU(+) cells (/mm2) 296.377.6 188.778.9a 168.477.9a
BrdU(+) vessels (/mm2) 107.876.6 80.475.4a 64.876.0a
BrdU, 5-bromodeoxyuridine; a-SMA, alpha-smooth muscle actin; TGF, transforming growth factor.
All values are mean7s.e. n=6 in each group. The number of positive cells or vessels was counted in 10 fields and represented as per mm2 of submesothelial fibrotic tissue by
measuring the fibrotic area using Micro-Analyzer software.
aPo0.05 vs CG-treated vehicle.
bPo0.05 vs endostatin peptide (1 mg/kg).
230 Kidney International (2007) 71, 227–238
o r i g i n a l a r t i c l e K Tanabe et al.: Endostatin treatment for peritoneal sclerosis
mice treated with endostatin peptide at 4 mg/kg 40.273.8,
Figure 5d and h).
The number of F4/80(þ ) cells per submesothelial area
(mm2) was also determined. Similar to the results obtained as
the number per field, therapeutic effects of endostatin
peptide on CG-induced monocyte/macrophage recruitment
were observed (Table 1).
Immunohistochemical analysis of cell proliferation in the
peritoneum
To determine the effect of endostatin peptide on the number
of cells undergoing DNA synthesis and proliferation,
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Figure 4 | Immunohistochemical analysis of type III collagen and
a-SMA. Accumulation of type III collagen in the peritoneum was
examined by indirect immunohistochemistry for the CG-injected
group (intraperitoneal) treated with the (a) vehicle or (b) endostatin
peptide at a dosage of 4 mg/kg. (c, e, and f) The distribution of a-SMA
in the peritoneum was examined by indirect immunohistochemistry
for the CG-injected group (intraperitoneal) treated with the vehicle,
or (d) endostatin peptide at a dosage of 4 mg/kg. (e, arrows) a-SMA-
positive cells were observed in the area under the mesothelial layer
and in (f, arrows) the area above the muscle layer. The representative
light microscopic appearance of the peritoneum is shown (a–d:
 200; e and f:  400 original magnification). (g) The increase in the
amount of immunoreactive type III collagen in the peritoneum as
detected by image analysis was significantly inhibited by treatment
with endostatin peptide. (h) Measurement of the number of a-SMA-
positive cells (per 10 fields at  400 original magnification) showed
the significant inhibitory effect of endostatin peptide. *Po0.01 vs C.
#Po0.01 vs V. n¼ 6. Each column consists of means7s.e.
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Figure 5 | Immunohistochemical analysis of TGF-b and F4/80.
(a, b, and e) Distribution of TGF-b. (c, d, and f) F4/80-positive
monocytes/macrophages were determined by indirect
immunohistochemistry for the CG-injected group (intraperitoneal)
treated with the (a, c, e, and f) vehicle or (b and d) endostatin peptide
at a dosage of 4 mg/kg. (e, arrows) TGF-b-positive cells were mainly
fibroblast-like cells. (c and f, arrows) CG injection markedly induced
the infiltration of F4/80-positive monocytes/macrophages in the
thickened submesothelial zone, and treatment with endostatin
peptide showed an inhibitory effect. The representative light
microscopic appearance of the peritoneum is shown (a–d:  200, e
and f:  400 original magnification). The increase in the number of
(g) TGF-b-positive cells as well as (h) monocyte/macrophage
infiltration was significantly suppressed by treatment with endostatin
peptide. *Po0.01 vs C. #P o0.05 vs V. n¼ 6. Each column consists of
means7s.e.
Kidney International (2007) 71, 227–238 231
K Tanabe et al.: Endostatin treatment for peritoneal sclerosis o r i g i n a l a r t i c l e
immunohistochemical staining for detecting the incorpora-
tion of 5-bromodeoxyuridine (BrdU) was performed. In the
vehicle-treated, CG-injected mice, the number of BrdU(þ )
cells was significantly increased compared to the normal
control group (200.879.0 vs 11.770.9, respectively, Figure
7a). According to the localization and morphological
appearance, incorporation of BrdU was observed in me-
sothelial cells, fibroblast-like spindle-shaped cells, and in
blood vessels in the CG-injected, vehicle-treated animals
(Figure 7c and d). Treatment with endostatin peptide
markedly decreased the number of BrdU(þ ) cells in the
peritoneum in a dose-dependent manner (CG-injected mice
treated with endostatin peptide at 1 mg/kg 114.775.1; and
CG-injected mice treated with endostatin peptide at 4 mg/kg
99.874.9, Figure 7b and e) as well as the number
of BrdU(þ ) blood vessels in the peritoneum (normal
control 1.070.6; CG-injected mice treated with the
vehicle 73.275.7; CG-injected mice treated with endostatin
peptide at 1 mg/kg 48.873.1; and CG-injected mice treated
with endostatin peptide at 4 mg/kg 38.573.6 /10 fields,
Figure 7f).
The number of BrdU(þ ) cells and BrdU(þ ) vessels per
submesothelial area (mm2) was also determined. Similar to
the results obtained as the number per field, therapeutic
effects of endostatin peptide on CG-induced cell proliferation
and endothelial cell growth were observed (Table 1).
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Figure 6 | Western blot analysis. Immunoblots for (a) VEGF, (c) TGF-b
and actin are shown. In each lane, 20mg protein obtained from the
peritoneal tissue was loaded. Each band was scanned and subjected
to densitometry. The intensities of (b) VEGF or (d) TGF-b protein
relative to actin are shown. *Po0.05 vs C. #Po0.05 vs V. n¼ 4 for each
group. Each column consists of means7s.e.
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Figure 7 | Immunohistochemical analysis of BrdU incorporation.
(a, c, and d) The distribution of BrdU-incorporating proliferating cells
in the peritoneum was determined by indirect
immunohistochemistry for the CG-injected group (intraperitoneal)
treated with the vehicle or endostatin peptide at a dosage of (b)
4 mg/kg. CG injection resulted in an increased number of BrdU-
incorporating cells in the thickened submesothelial zone, and
treatment with endostatin peptide showed an inhibitory effect.
(c, arrowheads) BrdU-incorporating cells were mainly endothelial
cells, (c, arrows) fibroblast-like cells, and (d, arrows) mesothelial cells.
The representative light microscopic appearance of the peritoneum is
shown (a and b:  200, c and d:  400 original magnification). The
increase in the number of (e) BrdU-incorporating cells as well as (f)
BrdU(þ ) blood vessels (per 10 fields at  400 original magnification)
was significantly suppressed by treatment with endostatin peptide.
*Po0.01 vs C. #Po0.05 vs V. n¼ 6. Each column consists of
means7s.e.
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Expression of a5b1-integrin and endostatin in the perito-
neum
We next studied the localization of a5b1-integrin, a
functional cell surface receptor for endostatin, and endostatin
in the peritoneum of the normal control and CG-injected
mice. Although the expression of a5-integrin was barely
observable in the peritoneum of the normal control mice, the
vehicle-treated, CG-injected mice revealed enhanced expres-
sion of a5-integrin in the peritoneum (Figure 8a). Double
immunofluorescent staining showed that a5-integrin in CG-
injected mice was mostly localized to endothelial cells
expressing CD31, suggesting the primary cells responsible
for the action of endostatin peptide to be vascular endothelial
cells. The immunoreactivity for endostatin was colocalized to
CD31-positive blood vessels in the peritoneum of the CG-
injected mice, but was barely detectable in the normal control
mice (Figure 8b). At a higher magnification, the immuno-
reactivity for endostatin in a linear pattern outlined the
CD31-positive endothelial cells (Figure 8c), suggesting that
endogenous endostatin was derived from the vascular
basement membranes in the peritoneum.
DISCUSSION
The population of patients with end-stage renal disease
requiring renal replacement therapy such as hemodialysis or
renal transplantation is increasing worldwide. Although PD is
an increasingly common alternative to hemodialysis, the
development of peritoneal dysfunction and peritoneal
sclerosis after long-term PD limits its usefulness.1,2
Type XVIII collagen is one of the major proteoglycans in
basement membranes composed of an N-terminal non-
collagenous domain, multiple interrupted triple-helical
regions, and a C-terminal non-collagenous domain 1.
Endostatin is the 20-kDa fragment of the non-collagenous
domain 1 of type XVIII collagen and possesses potent
antiangiogenic activity.20 Endostatin also serves as an
inhibitor of tumor and angiogenesis by suppressing the
endogenous expression of VEGF-A22 and by blocking VEGF-
A-mediated proangiogenic signaling via direct interaction
with flk-1.28 Inhibitory effects of endostatin on vascular
permeability in the retinal endothelium have been demon-
strated29 and collagen XVIII-knockout mice exhibited
increased vascular permeability in an atherosclerosis model,30
further supporting the regulatory role of endostatin in
vascular permeability. Recent reports have demonstrated the
therapeutic potential of endostatin in non-neoplastic,
chronic inflammatory disorders with the involvement of
angiogenic processes such as rheumatoid arthritis and
proliferative diabetic retinopathy.31,32 We recently observed
the therapeutic efficacy of the N-terminal endostatin peptide
in ameliorating early alterations in a diabetic nephropathy
mouse model.27 Based on our findings together with
accumulating evidence suggesting the involvement of angio-
genic processes in promoting peritoneal sclerosis prompted
us to evaluate the therapeutic efficacy of endostatin peptide
in this pathological situation.
Previous reports have described the involvement of
multiple factors such as endotoxin,33 acetate dialysate,4,33
advanced glycation end-products,34 and carbonyl modifica-
tion of peritoneal tissues35 in the pathogenesis of peritoneal
fibrosis. However, the underlying mechanisms in the
development of peritoneal sclerosis and EPS remain to be
elucidated.
In this study, we utilized a mouse experimental model of
peritoneal sclerosis induced by repeated injections of CG. The
importance of CG and alcohol, which was used to sterilize the
catheter in exchanging process, in the pathogenesis of EPS
has been described previously.36,37 Experimental peritoneal
fibrosis induced by repeated intraperitoneal injections of CG
in ethanol might not completely mimic peritoneal sclerosis
or EPS observed in patients on long-term PD. In fact, the
pathologic findings of EPS and peritoneal sclerosis are not
uniform and various factors are involved. In addition, certain
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c
Figure 8 | Expression of a5-integrin and endostatin in the
peritoneum. (a) Double immunofluorescent staining of a5-integrin
(red, endostatin receptor) and CD31 (green, an endothelial cell
marker) was performed to assess the localization and expression of
a5-integrin in the peritoneum. Although a5-integrin was faintly
observed in the peritoneum of the undiseased control mice (upper
panels), enhanced expression of a5-integrin colocalized with CD31
was observed in the peritoneum of the CG-injected mice (lower
panels, arrowheads). (b) Double immunofluorescent staining of
endogenous endostatin (red) and CD31 (green) was also performed.
Although endostatin was hardly observable in the peritoneum of the
undiseased control mice (upper panels), enhanced expression of
endostatin colocalized with CD31(þ ) blood vessels was observed in
the peritoneum of the CG-injected mice (lower panels, arrowheads).
(c) A higher magnification image ( 200) of the area (corresponding
to a red box in b) showed that immunoreactivity for endostatin
outlined the CD31-positive endothelial cells (arrowheads), suggesting
that endogenous endostatin was derived from vascular basement
membranes.
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common features are observed during the development of
peritoneal sclerosis between CG-induced experimental ani-
mal models and human patients undergoing long-term PD.
These common histological findings include increased
accumulation of interstitial collagens such as type I and III
collagen, infiltration of monocytes/macrophages, increase in
a-SMA-positive myofibroblasts, and vascular density in the
peritoneum.3–5,38 These similarities in alterations of the
peritoneal membranes between experimental CG models
and human PD patients suggest that the CG model is a
candidate model for examining the efficacy of various
potential therapeutic reagents for regulating peritoneal
sclerosis.
Currently, studies employing experimental peritoneal
sclerosis models induced by long-term exposure to dialysis
solutions are limited to rats or larger animals as far as we
know. Instead, experimental studies on mice exclusively
utilized a CG-induced peritoneal sclerosis model, most likely
due to the technical difficulty of maintaining abdominal
catheters inserted for a long period of time. On the other
hand, an experimental rat model necessitates the requirement
of a large amount of endostatin peptide compared with a
mouse model. For these reasons, we utilized a CG-induced
peritoneal sclerosis mouse model in the present study.
However, further studies using other experimental models
more relevant to peritoneal sclerosis in the clinical setting
would be favorable.
Continuous administration of endostatin peptide via
subcutaneous osmotic minipumps did not produce any
harmful side effects, similar to our recent observations using
this peptide as well as another endogenous angiogenesis
inhibitor, tumstatin peptide derived from type IV collagen
in a diabetic nephropathy model.27,39 In addition,
treatment with endostatin peptide did not give rise to any
pathological alterations in the heart, liver, or kidney and
failed to affect wound repair in accordance with previous
reports.27,40
Characteristic histological changes in peritoneal sclerosis
such as thickening of the submesothelial area and the
accumulation of type III collagen were significantly inhibited
by treatment with endostatin peptide. The pivotal role of
TGF-b1 in the development of peritoneal fibrosis has been
well characterized.12 Immunohistochemical analysis showed
the inhibitory effect of endostatin peptide on the number of
TGF-b(þ ) cells in the peritoneum. The inhibitory effect of
endostatin peptide on the accumulation of type III collagen
induced by CG-injection may be, at least in part, mediated
via its inhibitory effect on TGF-b expression. The role of
TGF-b in inducing EMT in renal disorders41 and peritoneal
fibrosis10,12 has been previously described. Immunoreactivity
for a-SMA and TGF-b was observed in the submesothelial
area in addition to the fibrotic area, suggesting a mechanism
involving EMT of mesothelial cells in the CG-injected mice.
Treatment with endostatin peptide suppressed the increase in
peritoneal a-SMA(þ ) cell number in the CG-injected mice
in parallel with its inhibitory effect on TGF-b expression and
accumulation of extracellular matrix. These results suggest
that the therapeutic effect of endostatin peptide on peritoneal
sclerosis may be associated with its regulatory role in EMT of
peritoneal mesothelial cells.
Immunohistochemical analysis revealed the presence of
BrdU(þ ) proliferating cells in blood vessels as well as in
fibroblast-like cells in the thickened submesothelial area in
the vehicle-treated CG-injected mice. Treatment with endo-
statin peptide significantly suppressed the number of
proliferating cells in blood vessels and the proliferation of
fibroblast-like cells, potentially associated with its inhibitory
effects on extracellular matrix accumulation. The suppressive
effect of endostatin peptide treatment on the proliferation of
fibroblast-like cells may be indirectly mediated through
factors secreted by endothelial cells, considering the known
endothelial cell-specific antiproliferative effect of endosta-
tin.20 Yoshio et al.19 reported the therapeutic effect of
antiangiogenic reagent TNP-470 in a similar experimental
mouse peritoneal fibrosis model. Together with the previous
report, our present findings demonstrate the suppressive
effect of angiogenesis inhibitors on peritoneal fibrosis via
regulating factors involved in matrix turnover.
The suppressive effect of endostatin peptide on the
increase in the number of CD31(þ ) blood vessels and
BrdU(þ ) vessels in the thickened submesothelial area may
be mediated via the potent antiangiogenic efficacy of
endostatin peptide, similar to its reported inhibitory effect
on tumor growth and metastasis.20
Injection of CG resulted in an increased number of
peritoneal VEGF-A(þ ) cells (mesothelial cells, vascular cells,
and spindle-shaped fibroblasts), and endostatin peptide
showed inhibitory effects. Considering the inhibitory effect
of endostatin on VEGF-A-induced angiogenesis in patholo-
gical conditions such as tumor22 and diabetic retinopathy,32
the antiangiogenic effect of endostatin peptide observed in
the present study may be attributed, at least in part, to its
inhibitory effect on VEGF-mediated signaling in analogy
with a previous report utilizing neutralizing anti-VEGF-A
antibodies.17
For the analysis of immunohistochemical findings, we
additionally performed measurement of the number of
CD31(þ ), VEGF(þ ), F4/80(þ ), a-SMA(þ ), TGF-b(þ ),
and BrdU(þ ) cells per submesothelial area (mm3) to
quantitatively evaluate these parameters. We observed results
similar to the measurement determined per field, demon-
strating the significant therapeutic effects of endostatin
peptide, not merely reflected by differences in submesothelial
thickening.
Considering the essential involvement of VEGF-A and
TGF-b(þ ) in peritoneal sclerosis, we further evaluated the
peritoneal protein levels of these factors by Western blot. The
results obtained by the quantitative immunoblot were
consistent with those of immunohistochemistry, further
confirming the therapeutic effects of endostatin peptide
mediated by regulating these key factors involved in
angiogenesis and fibrosis.
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Increased vascular density may lead to inflammatory cell
infiltration in cooperation with various chemotactic factors
and adhesion molecules synthesized by activated endothelial
cells.42 Previous reports have demonstrated the association
between inflammation and angiogenesis in chronic inflam-
matory disorders43,44 and therapeutic effects of antiangio-
genic agents have been reported.45 The inhibitory effects of
endostatin on vascular permeability,29 and the therapeutic
potential of endostatin in chronic inflammatory disorders
such as rheumatoid arthritis and diabetic retinopathy31,32
have been reported. Infiltration of monocytes/macrophages is
one of the characteristic pathological alterations frequently
observed in specimens of patients with EPS associated with
the extent of peritoneal fibrosis.46 In a CG-induced peritoneal
sclerosis model, angiogenesis may be associated with
peritoneal inflammation, eventually leading to fibrosis. Thus,
the observed inhibitory effects of endostatin peptide on
monocyte/macrophage infiltration in the peritoneal mem-
branes may derive from its inhibitory effect on angiogenesis.
In line with our findings, Yoshio et al.19 observed the anti-
inflammatory effect of antiangiogenic reagent TNP-470 in a
CG-induced peritoneal fibrosis mouse model.
The functional receptor for endostatin is considered to be
a5b1-integrin on endothelial cells25,47 and other cell surface
proteins including glypicans, flk-1, and E-selectin.26,28,48 As
the critical involvement of a5b1-integrin in mediating the
antiangiogenic capacity of endostatin has been reported,25 we
studied the localization of this cell surface receptor in the
peritoneum of the CG-injected mice. Although the expres-
sion of a5b1-integrin was not clearly observed in the
peritoneum of the normal control mice, increased expression
of a5b1-integrin colocalized with CD31 was observed in
blood vessels of the thickened submesothelial area in the CG-
injected mice as detected by double immunofluorescence.
These results suggest that the primary action of endostatin
peptide on peritoneal vascular endothelial cells potentially
mediated via a5b1-integrin might have lead to the observed
therapeutic effects in the CG-injected mice.
Endogenous levels of endostatin in the peritoneum were
increased in the vehicle-treated CG-injected mice, mainly
colocalized to blood vessels. These findings suggest the
potential feedback regulatory mechanism to maintain a
proper balance between proangiogenic and antiangiogenic
factors. However, this endogenous regulation of endostatin
may not be sufficient for inhibiting the progression of
peritoneal sclerosis, requiring exogenous administration of
endostatin peptide in this study.
Strategies utilizing endostatin peptide have several ad-
vantages over anti-VEGF-A antibodies such as, (1) the lack of
immune response owing to the origin of endostatin peptide
(endogenous human type XVIII collagen), and (2) feasibility
of the production of synthetic peptide at low cost.
In this study, we treated the CG-injected mice with
systemic administration of antiangiogenic endostatin pep-
tide. Systemic administration of antiangiogenic reagents may
lead to a reduced angiogenic response in a setting requiring
angiogenic neovessel formation such as myocardial infarction
or limb ischemia, and cardiovascular events complicated in
patients with end-stage renal disease. Here, we attempted to
observe the therapeutic effects of endostatin peptide in a
mouse peritoneal sclerosis model without renal dysfunction.
Further careful assessment of the therapeutic efficacy of
endostatin peptide on peritoneal sclerosis in the presence of
deteriorated renal function, that is, a 5/6 nephrectomy
model, will be required in future. Although we do not
consider the experimental CG-induced peritoneal fibrosis
model to be equivalent to peritoneal fibrosis in human
patients, it exhibits common characteristic pathological
features observed in human peritoneal fibrosis. These features
include accumulation of type III collagen, increased expres-
sion of TGF-b, VEGF, and a-SMA, and monocyte/macro-
phage infiltration. Therefore, we consider that the current
therapeutic effects observed in the mouse model could be the
initial process for translation into the development of
therapeutics for human PD patients.
In conclusion, we demonstrated that the administration of
antiangiogenic endostatin peptide effectively ameliorated
alterations in peritoneal sclerosis induced by injections of
CG, in addition to its known effects on treating tumor,
rheumatoid arthritis, neovascular retinopathy, and early
diabetic nephropathy.27 The therapeutic efficacy of endosta-
tin peptide observed in the present study suggests the
potential of this reagent as a candidate therapy in preventing
and treating clinical peritoneal sclerosis in patients under-
going long-term continuous ambulatory PD in future.
MATERIALS AND METHODS
Experimental protocols
The experimental protocol was approved by the Animal Ethics
Review Committee of Okayama University Graduate School of
Medicine, Dentistry, and Pharmaceutical Sciences. Female ICR mice
(Japan SLC, Shizuoka, Japan) at 6 weeks of age (26.971.5 g body
weight) were used in the present study. The mice were fed a standard
pellet laboratory chow and were provided with water ad libitum.
Peritoneal sclerosis was induced by intraperitoneal injections of
0.1% CG in 15% ethanol dissolved in saline as described previously
with some modifications.19,49 We performed preliminary experi-
ments to identify the optimal experimental schedule for observing
peritoneal fibrosis. The mice were given intraperitoneal injections of
0.25, 0.3, or 0.35 ml of CG every other day, over a period of 16, 20,
and 24 days (n¼ 3–4, each group). Marked peritoneal sclerosis was
observed in all mice at 24 days by injections of 0.35 ml of CG as
observed by the light microscopic appearance of the parietal
peritoneum stained with Masson’s trichrome (data not shown).
Lower dosages of CG or shorter time courses resulted in milder and
more infrequent development of peritoneal sclerosis. Therefore, we
performed the following experiments with injections of 0.1% CG at
a volume of 0.35 ml every other day over a period of 24 days. The
mice were divided into three subgroups: (1) endostatin peptide
treatment (1 mg/kg body weight), (2) endostatin peptide treatment
(4 mg/kg body weight), (3) vehicle buffer treatment (n¼ 6 for each
subgroup). Then, the mice of group (1) and (2) received continuous
infusion of endostatin peptide, and the mice of group (3) received
the vehicle buffer phosphate-buffered saline (PBS) via osmotic
Kidney International (2007) 71, 227–238 235
K Tanabe et al.: Endostatin treatment for peritoneal sclerosis o r i g i n a l a r t i c l e
minipumps (Alzet model 2004; Alza Corp., Palo Alto, CA, USA)
subcutaneously implanted on the day of the initial CG injection.
Intraperitoneal injection of CG was performed under ether
anesthesia to ensure the injection of accurate dosage. Another
group of mice received intraperitoneal injections of 15% ethanol in
saline every other day over a period of 24 days to serve as a control
group. All the mice were killed 24 days after starting CG injection.
The mice received an intraperitoneal injection of BrdU, 100 mg/kg
(Sigma-Aldrich Inc., St Louis, MO, USA) 4 h before killing. The
parietal peritoneal tissues were carefully dissected out, and were
either fixed in 10% formalin followed by paraffin embedding or
snap-frozen for histological evaluation. Intraperitoneal injections of
CG and BrdU in the present study were performed at the
lower portion of the abdomen, whereas the upper portion of
the peritoneum was processed for histological evaluation to
avoid mechanical damage of the peritoneum caused by repeated
injections.
Endostatin peptide (amino-acid sequence: H-HSHRDFQPVLHL
VALNSPLSGG MRGIR-OH) encompassing 1–27 amino-acid
portion of human endostatin, was synthesized and purified by
high-pressure liquid chromatography (Kurabou, Osaka, Japan and
Multiple Peptide Systems, San Diego, CA, USA) and characterized as
described previously.24,27,50 Endostatin peptide with a purity higher
than 97% was used and dissolved in PBS to be used for the animal
experiments. The dosage of endostatin peptide used in the present
study was determined according to a previous study using
endostatin peptide (5 mg/kg) and studies using recombinant
endostatin (0.3–10 mg/kg) in animal models.20,23 The dosage of
recombinant human endostatin (30–300 mg/m2/day) in human
clinical trials for patients with advanced solid tumors failed to
exhibit any toxic side effects,51 suggesting the feasibility of the
dosage utilized in the present study in humans.
Histological analysis
Formalin-fixed, paraffin-embedded sections (4mm) were stained
with Masson’s trichrome for light microscopic observation. The
thickness of the submesothelial collagenous zone above the
abdominal muscle layer in cross-sections of the abdominal wall
was defined as peritoneal thickness as described previously.19
Measurement of the peritoneal thickness was performed by image
analysis at  100 original magnification using Micro Analyzer
software ver.1.1 (Nippon Poldigital Co., Japan). In each image,
peritoneal thickness was measured at 10 different points. Peritoneal
fibrosis was defined as a submesothelial compact zone thickness
exceeding 8 mm based on the highest value recorded for control
subjects not receiving CG injections. Peritoneal cross-sections were
observed by two investigators and averaged to determine the
peritoneal thickness.
Immunohistochemistry
Immunohistochemistry was performed using 4 mm formalin-fixed,
paraffin-embedded sections as described previously.27,39 The
following antibodies were used as primary antibodies: (1) hamster
anti-mouse monoclonal CD31 antibody (1:50 dilution, MAB1398Z;
Chemicon International, Inc., Temecula, CA, USA); (2) rabbit
polyclonal anti-human VEGF antibody (1:100 dilution, sc-507;
Santa Cruz Biotechnology, Santa Cruz, CA, USA); (3) rat anti-
mouse F4/80 antibody (1:200 dilution, Serotec, Oxford, UK); (4)
monoclonal mouse anti-aSMA antibody (1:200 dilution, A2547;
Sigma, St Louis, MO, USA); (5) monoclonal mouse anti-BrdU
antibody (1:100 dilution, B2531; Sigma); (6) polyclonal rabbit anti-
mouse type-III collagen antibody (1:200 dilution, LB-1393; LSL Co.,
Tokyo, Japan); and (7) polyclonal rabbit anti-mouse TGF-b1
antibody (1:100 dilution, sc-146; Santa Cruz). Briefly, after
deparaffinization, the sections were treated with 0.3% H2O2 for
30 min to inactivate endogenous peroxidase activity. For immuno-
histochemistry of CD31, a-SMA, and BrdU, the sections were
treated with 0.1% trypsin for 30 min at 371C before H2O2 treatment
for antigen retrieval. The sections were then blocked with 3% bovine
serum albumin in PBS for 1 h, and were incubated with primary
antibodies as described above for 1 h. Then, the sections were
washed and incubated with biotinylated secondary antibodies for
40 min, and immunoperoxidase staining was conducted using the
Vectastain ABC Elite reagent kit (Vector Labs, Burlingame, CA,
USA). The following biotinylated antibodies were used as secondary
antibodies: (1) goat anti-hamster immunoglobulin (Ig)G for CD31
(1:250 dilution); (2) goat anti-rabbit IgG (Nichirei Bioscience,
Tokyo, Japan) for VEGF-A and TGF-b1 (1:250 dilution); and (3)
goat anti-rat IgG for F4/80 (1:250 dilution). Immunostaining for a-
SMA and BrdU were conducted using the M.O.M. Immunodetec-
tion kit (Vector Labs). Diamino-benzidine was used as a chromogen.
All slides were counterstained with methyl green. Normal mouse
IgG, rabbit IgG, hamster IgG, or rat IgG was used as a negative
control. The number of positively stained cells or blood vessels was
determined by observing more than 10 fields at  400 original
magnification in each section. In addition to this morphometric
analysis, we measured the submesothelial area in each image using
Micro Analyzer software and expressed positively stained vessels and
cells as the number per submesothelial area (mm2) in order to
exclude the influence of the submesothelial thickness on each
parameter.
To assess the type III collagen-positive area, the image files
(1392 1040 pixels) at  200 magnification were analyzed using
Lumina Vision software (Mitani, Fukui, Japan). The positive area
was shown as the average of diamino-benzidine-positive pixel values
obtained from five image files in each section.
Immunofluorescence
Double immunofluorescent staining was performed as described
previously.27 Briefly, frozen sections (4 mm) were fixed in cold
(201C) acetone for 3 min and then air dried. The sections were
blocked with 1% bovine serum albumin and then incubated with
primary antibodies, rat anti-mouse a5-integrin (BD Pharmingen,
San Diego, CA, USA), or goat anti-mouse endostatin antibody
(AF570; R&D Systems) for 1 h, followed by incubation with hamster
anti-mouse CD31 antibody (Chemicon) for 1 h. Subsequently, the
sections were washed three times in PBS and incubated with Alexa
Fluor 546-labeled goat anti-rat IgG (A11081; Invitrogen, Carlsbad,
CA, USA) or Alexa Fluor 546-labeled donkey anti-goat IgG
(A11056; Invitrogen) for 1 h followed by incubation with Alexa
Fluor 488-labeled goat anti-hamster IgG (A21110; Invitrogen) for
1 h. After three washes with PBS, Vectashield anti-fade mounting
medium (Vector Labs) was applied and the sections were observed
by a fluorescence microscope (BZ-Analyzer; Keyence, Osaka, Japan)
and images were obtained. Normal rat and hamster IgG were used as
negative controls.
Western blot
Western blot was performed as described previously.52,53 Briefly,
peritoneal tissues were homogenized in radioimmunoprecipitation
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assay buffer at 41C. After centrifugation at 14 000 r.p.m. for 30 min
at 41C, the supernatant was collected and stored at 801C until use.
The total protein concentration was determined by using the DC-
protein determination system (Biorad, Hercules, CA, USA) using
bovine serum albumin as a standard. The samples were processed
for sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and
the proteins were electrotransferred onto a nitrocellulose membrane
(Amersham, Piscataway, NJ, USA). The membranes were blocked
with 5% non-fat dry milk in 1X Tris-buffered saline containing 0.1%
Tween-20 for 1 h, incubated over night with polyclonal rabbit anti-
mouse TGF-b 1/2/3 (1:500 dilution; Santa Cruz) and anti-VEGF
(1:1000 dilution; Santa Cruz) antibodies at 41C. After incubation
with horseradish peroxidase-labeled anti-rabbit IgG antibodies for
1 h, signals were detected using an enhanced chemiluminescence
system (Amersham). The membranes were reprobed with rabbit
anti-actin antibodies (Chemicon) to serve as controls for equal
loading. The density of each band was determined using NIH
Image software, and expressed as a value relative to the density of
the corresponding band obtained from the actin immunoblot
(Figure 6).
Statistical analysis
All values are expressed as mean7s.e.m. A Kruskal–Wallis test
with post hoc comparisons using Scheffe’s test was employed
for inter-group comparisons of multiple variables. Statistical
analysis was performed by StatView software (Abacus Concepts,
Berkeley, CA, USA). A level of Po0.05 was considered statistically
significant.
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